Contrary to expectation: Preserved renal function after using PD-1 Inhibitor Cemiplimab-rwlc in a kidney transplant recipient
<p>The use of immune checkpoint inhibitors in transplant recipients with malignancy is associated with the risk of graft failure due to acute rejection. There is limited literature regarding the use of Cemiplimab-rwlc (Libtayo) in kidney transplant patients. Here we present a case of using Cem...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Book |
| Published: |
Archives of Organ Transplantation - Peertechz Publications,
2022-09-08.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | peertech__10_17352_2640-7973_000020 | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a Muhannad Leghrouz |e author |
| 700 | 1 | 0 | |a Svetomir N Markovic |e author |
| 700 | 1 | 0 | |a Aleksandra Kukla |e author |
| 245 | 0 | 0 | |a Contrary to expectation: Preserved renal function after using PD-1 Inhibitor Cemiplimab-rwlc in a kidney transplant recipient |
| 260 | |b Archives of Organ Transplantation - Peertechz Publications, |c 2022-09-08. | ||
| 520 | |a <p>The use of immune checkpoint inhibitors in transplant recipients with malignancy is associated with the risk of graft failure due to acute rejection. There is limited literature regarding the use of Cemiplimab-rwlc (Libtayo) in kidney transplant patients. Here we present a case of using Cemiplimab-rwlc (Libtayo), a Programmed Death receptor-1 (PD-1) blocking antibody for locally advanced and metastatic Cutaneous Squamous Cell Carcinoma (CSCC), in a kidney transplant recipient.</p><p><br></p> | ||
| 540 | |a Copyright © Muhannad Leghrouz et al. | ||
| 546 | |a en | ||
| 655 | 7 | |a Case Report |2 local | |
| 856 | 4 | 1 | |u https://doi.org/10.17352/2640-7973.000020 |z Connect to this object online. |